S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
NASDAQ:SRPT

Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

$115.62
-0.93 (-0.80%)
(As of 04/19/2024 ET)
Today's Range
$114.37
$117.74
50-Day Range
$115.62
$141.53
52-Week Range
$55.25
$159.89
Volume
641,236 shs
Average Volume
568,956 shs
Market Capitalization
$10.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$158.38

Sarepta Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
37.0% Upside
$158.38 Price Target
Short Interest
Healthy
4.90% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.56mentions of Sarepta Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$2.74 M Sold Last Quarter
Proj. Earnings Growth
273.71%
From $2.13 to $7.96 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.86 out of 5 stars

Medical Sector

23rd out of 909 stocks

Pharmaceutical Preparations Industry

9th out of 427 stocks

SRPT stock logo

About Sarepta Therapeutics Stock (NASDAQ:SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

SRPT Stock Price History

SRPT Stock News Headlines

A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
10 Unstoppable Stocks That Will Make You Richer
Pfizer: The Market Is Wrong
A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
SRPT Jun 2024 80.000 call
SRPT Mar 2024 80.000 put
See More Headlines
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/21/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
1,314
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$158.38
High Stock Price Target
$224.00
Low Stock Price Target
$109.00
Potential Upside/Downside
+37.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
15 Analysts

Profitability

Net Income
$-535,980,000.00
Pretax Margin
-41.83%

Debt

Sales & Book Value

Annual Sales
$1.24 billion
Book Value
$9.19 per share

Miscellaneous

Free Float
86,951,000
Market Cap
$10.86 billion
Optionable
Optionable
Beta
0.94

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Douglas S. Ingram Esq.Mr. Douglas S. Ingram Esq. (Age 61)
    President, CEO & Director
    Comp: $1.62M
  • Mr. Ian Michael Estepan (Age 48)
    Executive VP & CFO
    Comp: $917.53k
  • Dr. Louise R. Rodino-Klapac Ph.D. (Age 46)
    Executive VP, Chief Scientific Officer and Head of Research & Development
    Comp: $1.04M
  • Mr. Ryan E. Brown J.D. (Age 46)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $823.36k
  • Mr. Bilal Arif (Age 52)
    Executive VP & Chief Technical Operations Officer
  • Ms. Francesca T. Nolan
    Executive Director of Investor Relations and Corporate Communications
  • Ms. Alison Nasisi
    Executive VP & Chief People Officer
  • Dr. Diane L. Berry Ph.D.
    Executive VP and Chief of Global Policy & Advocacy Officer
  • Mr. Dallan Murray
    Executive VP & Chief Customer Officer
  • Mr. Will Tilton
    Senior VP, Head of Strategy & Chief of Staff

SRPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price target for 2024?

15 Wall Street analysts have issued 1 year target prices for Sarepta Therapeutics' shares. Their SRPT share price targets range from $109.00 to $224.00. On average, they predict the company's stock price to reach $158.38 in the next twelve months. This suggests a possible upside of 37.0% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2024?

Sarepta Therapeutics' stock was trading at $96.43 at the beginning of 2024. Since then, SRPT stock has increased by 19.9% and is now trading at $115.62.
View the best growth stocks for 2024 here
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings data on Wednesday, February, 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.50. The biotechnology company earned $396.80 million during the quarter, compared to analysts' expectations of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative trailing twelve-month return on equity of 18.97%. The company's revenue for the quarter was up 53.6% on a year-over-year basis. During the same period in the previous year, the company posted ($1.24) earnings per share.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.28%), Wealth Enhancement Advisory Services LLC (0.01%), Sumitomo Mitsui Trust Holdings Inc. (0.00%), Atwood & Palmer Inc. (0.00%), Handelsinvest Investeringsforvaltning (0.00%) and Hudson Capital Management LLC (0.00%). Insiders that own company stock include Bilal Arif, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Ian Michael Estepan, Kathryn Jean Boor, Louise Rodino-Klapac, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Sarepta Therapeutics have any subsidiaries?
The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.
Read More
This page (NASDAQ:SRPT) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners